Table 2Summary of the strength of evidence for KQ 3

OutcomeDomains Pertaining to SOEEffect Estimate (95% CI)SOE
Number of Studies (Subjects)Study Design/QualityConsistency DirectnessPrecision Publication Bias
Apixaban, rivaroxaban, dabigatrana
MortalityNRNANANAOutcome not reportedInsufficient
Symptomatic DVTNRNANANAOutcome not reportedInsufficient
Nonfatal PENRNANANAOutcome not reportedInsufficient
Symptomatic VTE16 (38,747)RCT/GoodNA
Indirect
Imprecise

None detected
Rivaroxaban vs. dabigatranLow
 RR=0.68 (0.21 to 2.23)
 RD=3 fewer (11 fewer to 4 more) events/1000 patients
Rivaroxaban vs. apixabanLow
 RR=0.59 (0.26 to 1.33)
 RD=4 fewer (9 fewer to 1 more)/1000 patients
Apixaban vs. dabigatranLow
 RR=1.16 (0.31 to 4.28)
 RD=1 more (7 fewer to 8 more)/1000 patients
Major bleeding16 (38,747)RCT/GoodNA
Indirect
Imprecise

None detected
Rivaroxaban vs. dabigatranLow
 RR=1.37 (0.21 to 2.23);
 RD=4 more (2 fewer to 11 more) events/1000 patients
Rivaroxaban vs. apixabanLow
 RR=1.59 (0.84 to 3.02);
 RD=5 more (2 fewer to 12 more)/1000 patients
Apixaban vs. dabigatranLow
 RR=1.16 (0.31 to 4.28);
 RD=0 (8 fewer to 7 more)/1000 patients
a

Data from Gómez-Outes, 2012.

Abbreviations: DVT=deep vein thrombosis; NA=not applicable; NR=not reported; PE=pulmonary embolism; RCT=randomized controlled trial; RD=risk difference; RR=risk ratio; SOE=strength of evidence; VTE=venous thromboembolism

From: EXECUTIVE SUMMARY

Cover of Comparative Effectiveness of Newer Oral Anticoagulants and Standard Anticoagulant Regimens for Thromboprophylaxis in Patients Undergoing Total Hip or Knee Replacement
Comparative Effectiveness of Newer Oral Anticoagulants and Standard Anticoagulant Regimens for Thromboprophylaxis in Patients Undergoing Total Hip or Knee Replacement [Internet].
Adam SS, McDuffie JR, Lachiewicz PF, et al.
Washington (DC): Department of Veterans Affairs (US); 2012 Dec.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.